Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial demonstrated a benefit with the addition of the anti-CD38 monoclonal antibody daratumumab to VRd. The CASSIOPEIA trial demonstrated the benefit of adding daratumumab to VTd. The FORTE trial demonstrated that KRd plus transplant led to high PFS, sustained MRD negativity leads to prolonged progression-free survival, and the addition of a proteasome inhibitor and an immunomodulatory drug leads to better survival outcomes in the maintenance stage.
Read more by clicking here.